Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant mFOLFOXIRI + camrelizumab + bevacizumab for non-MSI-H/dMMR locally advanced rectal adenocarcinoma
ChiCTR2100054182Phase 2Recruiting
- Sponsor
- Peking University Shougang Hospital
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, bevacizumab and folinic acid + 5-fluorouracil + oxaliplatin + irinotecan in rectal adenocarcinoma and colorectal cancer (CRC), sponsored by Peking University Shougang Hospital. Primary endpoint: Complete remission rate. Started Dec 2021; status: recruiting.
02
Drugs
camrelizumabbevacizumabfolinic acid + 5-fluorouracil + oxaliplatin + irinotecan
03
Conditions
rectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100054182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054182.